Salarius Announces Proposed Public Offering of Common Stock Houston, Texas

Salarius Announces Proposed Public Offering of Common Stock

Houston, Texas, July 29, 2020 (GLOBE NEWSWIRE) Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a

clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Salarius. The

offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.

A shelf registration statement on Form S-3 (File No. 333-231010) relating

to the shares was filed with the Securities and Exchange Commission (the SEC ) and was declared effective by the SEC on May 17, 2019. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the

offering, when available, may be obtained be obtained at the SEC s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Attn: Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy

these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, or epigenetic causes of cancers

and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius lead candidate, Seclidemstat, is currently in clinical development for treating Ewing

sarcoma, for which it has Fast Track Designation Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius is also developing Seclidemstat for a number of cancers, with a second Phase 1/2

clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers.

Forward-Looking Statements

This press release contains forward-looking statements within the Private Securities Litigation Reform Act of 1995, including statements that relate to the

offering, the expected completion of the offering, and other information that is not historical information. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may

cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions, the impact of the COVID-19 pandemic, and the

satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by Salarius is contained in the sections captioned Risk Factors in the preliminary prospectus

supplement and the accompanying prospectus related to the public offering filed with the SEC, including the documents incorporated by reference therein. Salarius disclaims any intention or obligation to update or revise any forward-looking

statements, whether as a result of new information, future events, or otherwise.

Tiberend Strategic Advisors, Inc.

(212) 375-2664 / 2694

Tiberend Strategic Advisors, Inc.